Board to approve September 2026 results and interim dividend

Results View source PDF Explain this filing

AMRUTANJAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.3%Reaction day

₹489.10

prior close

₹492.70

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+1.3% vs market

Pharmaceuticals peers, median of 170sector+0.6%+0.8% vs sector

On the reaction day the stock moved 1.3 pts more than Nifty Microcap 250 and 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-0.9

15m

-0.8

30m

+0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.3+0.1+1.3+0.6+0.8

Next day

+0.8pendingpending+1.1-0.3

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board will meet on November 3, 2026 to approve unaudited financial results and the limited review report for the quarter and half year ended September 30, 2026. It will also consider the first interim dividend for 2026-27. No results or dividend amount is provided yet.

Likely market impact

Results and the dividend amount are pending, so there is no clear basis yet to assess earnings or share price impact.